Transcend Capital Advisors LLC Decreases Stock Holdings in Kenvue Inc. $KVUE

Transcend Capital Advisors LLC decreased its holdings in shares of Kenvue Inc. (NYSE:KVUE) by 26.6% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 50,755 shares of the company’s stock after selling 18,440 shares during the period. Transcend Capital Advisors LLC’s holdings in Kenvue were worth $1,062,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also recently made changes to their positions in the business. Evergreen Wealth Solutions LLC lifted its position in shares of Kenvue by 2.6% during the 1st quarter. Evergreen Wealth Solutions LLC now owns 16,769 shares of the company’s stock valued at $402,000 after buying an additional 432 shares in the last quarter. Wealth Alliance LLC lifted its position in shares of Kenvue by 1.6% during the 1st quarter. Wealth Alliance LLC now owns 31,778 shares of the company’s stock valued at $762,000 after buying an additional 486 shares in the last quarter. Everett Harris & Co. CA lifted its position in shares of Kenvue by 1.4% during the 1st quarter. Everett Harris & Co. CA now owns 36,971 shares of the company’s stock valued at $887,000 after buying an additional 500 shares in the last quarter. Proffitt & Goodson Inc. lifted its position in shares of Kenvue by 8.2% during the 2nd quarter. Proffitt & Goodson Inc. now owns 6,831 shares of the company’s stock valued at $143,000 after buying an additional 517 shares in the last quarter. Finally, UMB Bank n.a. lifted its holdings in Kenvue by 22.3% in the 2nd quarter. UMB Bank n.a. now owns 2,853 shares of the company’s stock valued at $60,000 after purchasing an additional 521 shares in the last quarter. Hedge funds and other institutional investors own 97.64% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts have weighed in on the company. Barclays decreased their price objective on Kenvue from $20.00 to $17.00 and set an “equal weight” rating on the stock in a report on Wednesday, October 1st. Jefferies Financial Group decreased their price objective on Kenvue from $25.00 to $23.00 and set a “buy” rating on the stock in a report on Monday. JPMorgan Chase & Co. decreased their price objective on Kenvue from $24.00 to $21.00 and set an “overweight” rating on the stock in a report on Friday, October 10th. Redburn Partners set a $22.00 price objective on Kenvue in a report on Friday, September 26th. Finally, The Goldman Sachs Group decreased their price objective on Kenvue from $22.00 to $19.00 and set a “neutral” rating on the stock in a report on Thursday, October 2nd. One investment analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, nine have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $20.90.

Kenvue Stock Up 0.3%

Shares of KVUE opened at $15.04 on Tuesday. The firm has a market cap of $28.87 billion, a P/E ratio of 20.33, a price-to-earnings-growth ratio of 2.16 and a beta of 0.72. Kenvue Inc. has a 12-month low of $14.05 and a 12-month high of $25.17. The company’s 50-day moving average price is $17.78 and its 200 day moving average price is $20.74. The company has a current ratio of 0.98, a quick ratio of 0.68 and a debt-to-equity ratio of 0.66.

Kenvue (NYSE:KVUE) last issued its quarterly earnings data on Thursday, August 7th. The company reported $0.29 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.28 by $0.01. The firm had revenue of $3.84 billion for the quarter, compared to analyst estimates of $3.94 billion. Kenvue had a net margin of 9.37% and a return on equity of 20.06%. Kenvue’s revenue was down 4.0% on a year-over-year basis. During the same period in the previous year, the firm earned $0.32 EPS. Kenvue has set its FY 2025 guidance at 1.000-1.050 EPS. On average, sell-side analysts forecast that Kenvue Inc. will post 1.14 earnings per share for the current year.

Kenvue Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Wednesday, August 27th. Investors of record on Wednesday, August 13th were issued a $0.2075 dividend. This is an increase from Kenvue’s previous quarterly dividend of $0.21. The ex-dividend date was Wednesday, August 13th. This represents a $0.83 annualized dividend and a yield of 5.5%. Kenvue’s payout ratio is presently 112.16%.

About Kenvue

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.